Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hua Medicine's Free Cash Flow for the
six
months ended in Dec. 2025 was HK$34.0 Mil. Hua Medicine's Revenue for the
six
months ended in Dec. 2025 was HK$304.4 Mil. Therefore, Hua Medicine's FCF Margin % for the quarter that ended in Dec. 2025 was 11.17%.
The historical data trend for Hua Medicine's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Hua Medicine's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HKSE:02552) has a FCF Margin % of 11.17% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hua Medicine and its competitors. According to the industry distribution chart, Hua Medicine ranks #732 out of 962 companies in the Drug Manufacturers industry, placing it in the top 76.1%.
Is Hua Medicine's FCF Margin % too high?
Hua Medicine's current FCF Margin % is 11.17%. The Drug Manufacturers industry median FCF Margin % is 2.48. Hua Medicine's value of 11.17% is 350.4% above this industry median. Based on the distribution chart, Hua Medicine ranks #732 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #732 out of 962 companies for FCF Margin %. This places Hua Medicine in the lower half of its industry. The industry median FCF Margin % is 2.48. Hua Medicine's value of 11.17% is 350.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current FCF Margin % of 11.17% is 350.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current FCF Margin % is 11.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HKSE:02552) is currently considered Possible Value Trap. The stock's GF Value™ is HK$8.74, compared to a current price of HK$2.51 — trading 71.3% below its estimated fair value. The current FCF Margin % is 11.17% and 350.4% above the Drug Manufacturers industry median of 2.48. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hua Medicine (HKSE:02552), the current FCF Margin % is 11.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HKSE:02552) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of HK$2.51 is trading 71.3% below its estimated GF Value™ of HK$8.74.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HKSE:02552:
FCF Margin %: 11.17%
GF Value™: HK$8.74 vs. price of HK$2.51 (71.3% below fair value)
Industry Position: 350.4% above the Drug Manufacturers median (#732 of 962)
No single metric tells the full story. See the HKSE:02552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score
Get the complete analysis for HKSE:02552
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02552 has been successfully added to your 
